Literature DB >> 2241948

Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis.

T Ozawa1, M Tanaka, S Ikebe, K Ohno, T Kondo, Y Mizuno.   

Abstract

Deleted mitochondrial DNA (mtDNA) was accumulated in the parkinsonian striatum, but the same deleted mtDNA was also detectable in the control striatum when cycles of polymerase chain reaction were increased. To discriminate between these pathological and physiological conditions, we quantitatively analyzed the proportion of deleted mtDNA to normal mtDNA by measuring the incorporation of alpha-[32P]deoxycytosine triphosphate into mtDNA fragments by using a laser image analyzer. To estimate the molar ratio of the deleted mtDNA to normal mtDNA, the radioactivity was normalized by each fragment size. By plotting logarithms of normalized radioactivities against PCR amplification cycles, straight lines were obtained with different slopes. By extrapolation of the line to the zero amplification, the proportion of mutant mtDNA to normal mtDNA in the original sample from the parkinsonian striatum was estimated to be ca. 5%, which was at least ten times higher than the proportion of ca. 0.3% in the control striatum. These results indicate that phenotype of the mutant mtDNA as Parkinson's disease is expressed when the proportion of deleted mtDNA to normal mtDNA exceeds a threshold of ten times higher value than in the normal subject.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2241948     DOI: 10.1016/0006-291x(90)90698-m

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Deletions of the mitochondrial genome.

Authors:  A E Harding; S R Hammans
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 2.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

Review 3.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

4.  Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

Authors:  S Koseki; T Tanabe; K Tani; S Asano; T Shioda; Y Nagai; T Shimada; J Ohkawa; K Taira
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

5.  Inherited and somatic mitochondrial DNA mutations in Guam amyotrophic lateral sclerosis and parkinsonism-dementia.

Authors:  Dana M Reiff; Rita Spathis; Chim W Chan; Miguel G Vilar; Krithivasan Sankaranarayanan; Daniel Lynch; Emily Ehrlich; Samantha Kerath; Risana Chowdhury; Leah Robinowitz; J Koji Lum; Ralph M Garruto
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

Review 6.  Mitochondrial involvement in the ageing process. Facts and controversies.

Authors:  E J Brierley; M A Johnson; O F James; D M Turnbull
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

Review 7.  Nuclear and mitochondrial genetics in Parkinson's disease.

Authors:  A H Schapira
Journal:  J Med Genet       Date:  1995-06       Impact factor: 6.318

Review 8.  The development of mitochondrial medicine.

Authors:  R Luft
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

Review 9.  Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas.

Authors:  Estela Area-Gomez; Cristina Guardia-Laguarta; Eric A Schon; Serge Przedborski
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

10.  Age-associated damage in mitochondrial DNA in human hearts.

Authors:  M Hayakawa; S Sugiyama; K Hattori; M Takasawa; T Ozawa
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.